NuCana (NCNA) Lowered to Hold at Zacks Investment Research

NuCana (NASDAQ:NCNA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

NCNA has been the subject of several other research reports. Jefferies Group assumed coverage on shares of NuCana in a report on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price for the company. Citigroup assumed coverage on shares of NuCana in a report on Monday, October 23rd. They issued a “buy” rating and a $23.00 target price for the company. William Blair assumed coverage on shares of NuCana in a research report on Monday, October 23rd. They set an “outperform” rating for the company. Finally, Cowen assumed coverage on shares of NuCana in a research report on Monday, October 23rd. They set an “outperform” rating for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $20.00.

Shares of NuCana (NASDAQ NCNA) opened at $12.29 on Tuesday. NuCana has a 1-year low of $9.32 and a 1-year high of $19.95.

A number of institutional investors and hedge funds have recently bought and sold shares of NCNA. Baillie Gifford & Co. bought a new position in NuCana during the third quarter valued at about $8,266,000. Sphera Funds Management LTD. bought a new position in NuCana during the third quarter valued at about $919,000. Citadel Advisors LLC bought a new position in NuCana during the third quarter valued at about $1,218,000. Alyeska Investment Group L.P. bought a new position in NuCana during the third quarter valued at about $2,296,000. Finally, Perceptive Advisors LLC bought a new position in NuCana during the third quarter valued at about $3,674,000. Institutional investors own 22.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “NuCana (NCNA) Lowered to Hold at Zacks Investment Research” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.com-unik.info/2018/01/09/nucana-ncna-lowered-to-hold-at-zacks-investment-research.html.

NuCana Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit